Low-dose vs standard-dose minocycline in bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized controlled, noninferiority trial

Table 3 Adverse events between the two groups, n (%)

Variables	Low-dose group (n = 120)	Standard-dose group (n = 120)	P value
Total	22 (18.3)	39 (32.5)	0.012a
AE grade
Mild	11 (9.2)	24 (20.0)	0.017a
Moderate	5 (4.2)	12 (10.0)	0.078
Severe	6 (5.0)	3 (2.5)	0.497
Main AE
Anorexia	2 (1.7)	5 (4.2)	0.443
Nausea	3 (2.5)	5 (4.2)	0.719
Vomiting	4 (3.3)	5 (4.2)	1.000
Diarrhea	5 (4.2)	6 (5.0)	0.760
Bloating	6 (5.0)	8 (6.7)	0.582
Skin rash	1 (0.8)	5 (4.2)	0.215
Dizziness	1 (0.8)	5 (4.2)	0.215
Discontinued due to AEs
Severe diarrhea	4 (3.3)	1 (0.8)	0.366
Vomiting	2 (1.7)	2 (1.7)	1.000
Personal reasons	2 (1.7)	3 (2.5)	1.000
Compliance	118 (98.3)	117 (97.5)	1.000

^aP < 0.05.

AE: Adverse event.